What is Solace Therapeutics?
Solace Therapeutics operates at the intersection of medical device innovation and women's health, specifically targeting the estimated 15 million adult women in the United States suffering from SUI. Unlike traditional market incumbents that rely on absorbent products and protective pads, Solace is pioneering an office-based treatment modality designed to restore quality of life. The company's market position is defined by its focus on clinical efficacy and patient-centric care, aiming to shift the paradigm from passive symptom management to active, medical intervention. By addressing the underlying physiological causes of incontinence, Solace is carving out a specialized niche within the broader femtech and urology sectors, providing a scalable alternative to existing non-medical solutions.
How much funding has Solace Therapeutics raised?
Solace Therapeutics has raised a total of $20.4M across 4 funding rounds:
Private Equity
$7M
Private Equity
$13M
Debt
$150K
Debt
$233K
Private Equity (2012): $7M, investors not publicly disclosed
Private Equity (2016): $13M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Debt (2021): $233K featuring PPP
Key Investors in Solace Therapeutics
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer participating in the private equity rounds to facilitate long-term clinical development.
Undisclosed Investor
A strategic partner focused on the advancement of medical device technologies within the women's health sector.
What's next for Solace Therapeutics?
With the recent influx of capital, Solace Therapeutics is poised to accelerate its go-to-market strategy and expand its clinical footprint. The company's roadmap likely involves scaling its office-based treatment delivery model and deepening its engagement with healthcare providers to ensure widespread adoption. As the firm moves into this enterprise-level growth phase, the focus will shift toward optimizing supply chain logistics, securing further regulatory milestones, and potentially exploring strategic partnerships to enhance its distribution network. The objective remains clear: to establish a new standard of care for SUI, thereby reducing the reliance on palliative products and improving long-term patient outcomes in the women's health market.
See full Solace Therapeutics company page
